This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

---

B2

**24.** (Currently Amended) A compound of the formula (I):



I

wherein:

A is a member selected from the group consisting of:

benzene, thiophene, furan, pyrrole, indole,



and

wherein

each B is independently selected from the group consisting of -C(-$R^1$)(-$R^2$)-, -O- and -N(-J-$R^3$)-, wherein not more than one B in any ring is either -O- or -N(-J-$R^3$)-;

each m and n is independently an integer from 0 to 4;

each q is independently an integer from 0 to 8;

Y is a member selected from the group consisting of -$(CH_2)_q$-, -$(CH_2)_m$O- and -$(CH_2)_m$-N(-$J^1$-)-$R^4$;

Z is a member selected from the group consisting of $-(CH_2)_n-C(=O)-NHOH$, $-(CH_2)_nCOOH$, $-(CH_2)_nCOOMe$ and $-(CH_2)_nCOOEt$;

L is a member selected from the group consisting of $-(CH_2)_q-$, $-(CH_2)_mO-$ and $-(CH_2)_m-N-(-J^2-)-R^5$;

J, $J^1$ and $J^2$ are each independently selected from the group consisting of C(=O) and a bond;

$R^1$ is a member selected from the group consisting of H, $-N(-J^3-R^6)(-J^4-R^7)$ and $-O-J^5-R^8$, wherein $J^3$, $J^4$ and $J^5$ are each independently selected from the group consisting of -C(=O)- and a bond, wherein at least one of $J^3$ and $J^4$ is a bond;

$R^2$ is a member selected from the group consisting of H, $-N(-J^6-R^9)(-J^7-R^{10})$ and $-O-J^8-R^{11}$, wherein $J^6$, $J^7$ and $J^8$ are independently selected from the group consisting of -C(=O)- and a bond, wherein at least one of $J^6$ and $J^7$ is a bond;

$R^3$ is a member selected from the group consisting of H, $C_1$-$C_8$ alkyl, $CF_3$ and $O-R^{12}$;

$R^4$ is a member selected from the group consisting of H, $C_1$-$C_8$ alkyl, $CF_3$ and $O-R^{13}$;

$R^5$ is a member selected from the group consisting of H, $C_1$-$C_8$ alkyl, $CF_3$ and $O-R^{14}$;

$R^6$ is a member selected from the group consisting of H, $C_1$-$C_8$ alkyl, $CF_3$ and $O-R^{15}$;

$R^7$ is a member selected from the group consisting of H, $C_1$-$C_8$ alkyl, $CF_3$ and $O-R^{16}$;

$R^8$ is a member selected from the group consisting of H, $C_1$-$C_8$ alkyl, $CF_3$ and $O-R^{17}$;

$R^9$ is a member selected from the group consisting of H, $C_1$-$C_8$ alkyl, $CF_3$ and $O-R^{18}$;

$R^{10}$ is a member selected from the group consisting of H, $C_1$-$C_8$ alkyl, $CF_3$ and $O-R^{19}$;

$R^{11}$ is a member selected from the group consisting of H, $C_1$-$C_8$ alkyl, $CF_3$ and O-$R^{20}$;

$R^{12}$, $R^{13}$, $R^{14}$, $R^{15}$, $R^{16}$, $R^{17}$, $R^{18}$, $R^{19}$ and $R^{20}$ are each independently selected from the group consisting of $C_1$-$C_4$ alkyl, cycloalkyl and benzyl;

and all pharmaceutically acceptable **stereo**isomers, salts, hydrates, solvates**, esters** and ~~**prodrug derivatives**~~ **amides** thereof.

**25.** (Currently Amended) The compound according to claim **24** wherein A is a member selected from the group consisting of:




**26.** (Previously Added) The compound according to claim **24** wherein A is a member selected from the group consisting of:




Y is a member selected from the group consisting of -$(CH_2)_q$- and -$(CH_2)_m$O-;

L is a member selected from the group consisting of -$(CH_2)_q$- and -$(CH_2)_m$O-; and

$R^1$ is a member selected from the group consisting of H and -O-$J^5$-$R^8$; and

$R^2$ is a member selected from the group consisting of H and -O-$J^8$-$R^{11}$;

and all pharmaceutically acceptable salts thereof.

B3

**27.** (Currently Amended) The compound according to claim **24**, wherein A is a member selected from the group consisting of:



and



Y is a member selected from the group consisting of -$(CH_2)_q$- and -$(CH_2)_m$O-;

L is a member selected from the group consisting of -$(CH_2)_q$- and -$(CH_2)_m$O-; and

$R^1$ is a member selected from the group consisting of H and -O-$J^5$-$R^8$; and

$R^2$ is a member selected from the group consisting of H and -O-$J^8$-$R^{11}$;

and all pharmaceutically acceptable salts thereof.

**28.** (Previously Added) The compound according to claim **24** wherein A is a member selected from the group consisting of:



and



wherein

each B is $CH_2$;

Y is a member selected from the group consisting of -$(CH_2)_q$- and -$(CH_2)_m$O-;

Z is -$(CH_2)_n$-C(=O)-NHOH;

L is -$(CH_2)_q$-;

each m and n is independently an integer from 0 to 4; and

each q is independently an integer from 0 to 8;

and all pharmaceutically acceptable salts thereof.

**29**. (Previously Added) A pharmaceutical composition comprising an effective amount of a compound according to claim **24**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

**30**. (Previously Added) The pharmaceutical composition comprising an effective amount of a compound according to claim **25**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

**31**. (Previously Added) The pharmaceutical composition comprising an effective amount of a compound according to claim **26**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

**32**. (Previously Added) The pharmaceutical composition comprising an effective amount of a compound according to claim **27**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

**33**. (Previously Added) The pharmaceutical composition comprising an effective amount of a compound according to claim **28**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

**34**. (Previously Added) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim **29** to said patient.

**35**. (Previously Added) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim **30** to said patient.

**36**. (Previously Added) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim **31** to said patient.

**37**. (Previously Added) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim **32** to said patient.

38. (Previously Added) A method of inhibiting adenylyl cyclase in a patient having a disease or condition modulated by elevated levels of adenylyl cyclase activity, comprising administering a composition according to claim **33** to said patient.

39. (Previously Added) The method according to claim **34**, further comprising inhibiting or preventing a patient's fibroproliferative vasculopathy following vascular injury or a vascular surgical operation, wherein said composition is administered to a patient in an effective amount subsequent to a vascular injury, or subsequent to a vascular surgical operation.

40. (Previously Added) The method according to claim **39** wherein the composition is administered for one to two weeks after the injury or surgical operation.

41. (Previously Added) The method according to claim **40** wherein fibroproliferative vasculopathy is caused by chronic allograft rejection and vascular restenosis following vascular trauma.

42. (Previously Added) A method of treating congestive heart failure comprising administering an effective amount of a pharmaceutical composition according to claim **29** to a patient in need thereof.

43. (Previously Added) A method of treating congestive heart failure comprising administering an effective amount of a pharmaceutical composition according to claim **30** to a patient in need thereof.

44. (Previously Added) A method of treating congestive heart failure comprising administering an effective amount of a pharmaceutical composition according to claim **31** to a patient in need thereof.

45. (Previously Added) A method of treating congestive heart failure comprising administering an effective amount of a pharmaceutical composition according to claim **32** to a patient in need thereof.

**46**. (Previously Added) A method of treating congestive heart failure comprising administering an effective amount of a pharmaceutical composition according to claim **33** to a patient in need thereof.